Eli Lilly and Company (LLY) — Company Research

Last Updated: 16 May 2026

Eli Lilly and Company (NYSE: LLY) is one of the world's largest pharmaceutical companies, headquartered in Indianapolis, Indiana, and founded in 1876. The company has transformed into the world's most valuable pharmaceutical business, driven by the extraordinary commercial success of tirzepatide — marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. With FY2025 revenue of $65.2bn and a market capitalisation exceeding $950bn, Lilly sits at the epicentre of the GLP-1 revolution reshaping global healthcare. For general market data, visit ChartsView Live Charts.

1. Company Snapshot

Field	Value
Full name	Eli Lilly and Company
Ticker	NYSE: LLY
Sector	Healthcare
Industry	Pharmaceuticals
Founded	1876, Indianapolis, Indiana, USA
Headquarters	Indianapolis, Indiana, USA
CEO	David A. Ricks (Chairman & CEO since January 2017)
Market cap	~$951bn (May 2026, per web search)
Revenue (FY2025)	$65.2bn
Net income (FY2025, GAAP)	~$20.6bn
Employees	~45,000 (approximate, per FY2025 annual report)
Primary exchange	NYSE (also Frankfurt: LLIA)
Fiscal year end	31 December
Website	lilly.com / investor.lilly.com

2. Bull Case vs Bear Case

Distilled from the full report below — factual only, no ratings.

Bull Case

• Tirzepatide dominance: Mounjaro and Zepbound (both tirzepatide) generated an estimated combined $31bn+ in FY2025 revenue, making tirzepatide one of the fastest-selling drugs in pharmaceutical history. Clinical superiority over semaglutide in head-to-head trials supports continued market-share gains.
• Pipeline depth: Retatrutide (triple agonist GIP/GLP-1/glucagon) is in Phase 3 for obesity, oral GLP-1 (Foundayo/orforglipron) launched April 2026 for diabetes, and oral tirzepatide is in development — extending the franchise beyond injectable therapy.
• Revenue acceleration: FY2025 revenue of $65.2bn represented 44.8% YoY growth; management raised FY2026 guidance to $82–85bn (per Q1 2026 earnings call), implying continued 26–30% growth as manufacturing capacity scales.
• Alzheimer's franchise emerging: Kisunla (donanemab) received FDA approval in July 2024 for early symptomatic Alzheimer's disease, opening a new therapeutic area with multi-billion-dollar long-term potential.
• Manufacturing investment: Lilly has committed over $23bn in US manufacturing expansion since 2023, with a further $4.5bn Indiana investment announced May 2026, building durable supply infrastructure to meet GLP-1 demand.

Bear Case

• IRA drug pricing risk: Under the Inflation Reduction Act, Mounjaro/tirzepatide is a candidate for Medicare price negotiation, which could materially compress margins on a product that represents the majority of revenue.
• GLP-1 competition intensifying: Novo Nordisk's Ozempic/Wegovy franchise commands significant market share; multiple oral GLP-1 candidates from Roche, Viking Therapeutics, and others are advancing in trials, threatening long-term tirzepatide pricing power.
• High valuation concentration risk: At P/FCF ~106x and EV/EBITDA ~35x, the stock embeds significant growth expectations. A clinical setback, slower uptake, or pricing pressure on tirzepatide would disproportionately affect the valuation.
• Manufacturing execution risk: The $23bn+ US manufacturing expansion is the largest in Lilly's history. Construction delays, regulatory approval lags at new sites, or quality control failures could constrain supply and revenue.
• GAAP vs. non-GAAP gap: Significant acquired in-process R&D (IPR&D) charges and amortisation of intangibles from acquisitions reduce reported GAAP earnings relative to non-GAAP; investors tracking GAAP metrics face higher apparent valuations than non-GAAP-focused analysis suggests.

3. What Does This Company Actually Do?

Eli Lilly discovers, develops, manufactures, and sells prescription medicines primarily in the areas of diabetes, obesity, oncology, immunology, and neuroscience. Founded by Colonel Eli Lilly in 1876, it is now the world's largest pharmaceutical company by market capitalisation. The company sells branded, patent-protected drugs to pharmacies, hospitals, pharmacy benefit managers (PBMs), and government healthcare programmes in over 110 countries. It earns revenue when patients (via insurers, PBMs, or out-of-pocket) pay for its drugs, and retains pricing power while patents are in force.

The commercial centrepiece is tirzepatide (GIP/GLP-1 dual agonist), sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management. Tirzepatide has demonstrated superior efficacy to existing GLP-1 agonists in clinical trials and became one of the fastest-adopted new drugs in US history after its 2022 launch. By FY2025, tirzepatide products alone represented the majority of Lilly's revenue. The company also has a significant oncology portfolio led by Verzenio (abemaciclib for breast cancer) and an emerging Alzheimer's franchise via Kisunla (donanemab).

Geographic revenue is predominantly US-driven (~70%) given tirzepatide's US coverage and the US market's premium pricing structure, though international expansion is accelerating as regulatory approvals widen.

Segment	% of revenue	What it is
Diabetes & Obesity (Incretin medicines)	~71% (~$46.3bn)	Mounjaro (tirzepatide, type 2 diabetes), Zepbound (tirzepatide, chronic weight management), Trulicity (dulaglutide, legacy GLP-1 now declining as tirzepatide cannibalises), Humalog and Humulin (insulin, established products in decline). This segment has driven virtually all of Lilly's revenue acceleration since 2022.
Oncology	~12% (~$7.8bn)	Verzenio (abemaciclib for HR+/HER2- breast cancer, adjuvant and metastatic) generates the majority; Cyramza (ramucirumab for multiple GI and lung cancers) and Jaypirca (pirtobrutinib for B-cell malignancies) contribute smaller but growing amounts. Verzenio has grown to become a global blockbuster with ~$5.5bn in annual revenue.
Immunology	~7% (~$4.6bn)	Taltz (ixekizumab for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis), Olumiant (baricitinib for rheumatoid arthritis and alopecia areata), and Ebglyss/Kynmobi (lebrikizumab for atopic dermatitis, expanding internationally). Competition from newer biologics and biosimilars creates pricing pressure.
Neuroscience	~3% (~$2.0bn)	Emgality (galcanezumab, preventive migraine), Kisunla (donanemab, early symptomatic Alzheimer's disease, FDA-approved July 2024 and ramping commercially), and Jardiance co-promotion revenue (empagliflozin via alliance with Boehringer Ingelheim).
Other pharmaceutical	~7% (~$4.5bn)	Established and legacy products including Forteo (teriparatide for osteoporosis), Alimta (pemetrexed, now largely off-patent), Cialis generic revenue, and various ex-US products. Revenue in this segment is in structural decline.

4. The Business Model

How Lilly makes money. Eli Lilly generates revenue by selling branded, patent-protected prescription medicines at premium prices. The core model is: invest heavily in R&D to discover or acquire differentiated drugs, obtain regulatory approval and patent protection, then commercialise globally over the patent life (typically 10–20 years from filing). Revenues are primarily collected from pharmacy benefit managers, wholesalers, hospitals, and government programmes, with net realised prices reflecting list prices minus rebates. The tirzepatide franchise (Mounjaro + Zepbound) exemplifies this model: a novel molecule with demonstrated superiority, priced at ~$1,000/month in the US (before rebates), yielding extraordinary margins.

Unit economics. Lilly's gross margin is typically 80%+ on branded drugs, reflecting very low marginal manufacturing costs relative to R&D-amortised pricing. Operating margin for FY2025 was significantly impacted by $7.84bn in capital expenditure (manufacturing scale-up) and elevated R&D spending (~$10bn+). Net income of ~$20.6bn on $65.2bn revenue implies a net margin of approximately 32%. The non-GAAP adjusted EPS of $24.21 vs GAAP EPS of $22.95 reflects primarily amortisation of intangibles and acquired IPR&D charges. FCF was $8.97bn (operating cash flow $16.81bn minus capex $7.84bn per FY2025 cash flow statement).

Moat. Lilly's competitive position rests on: (1) patent exclusivity on tirzepatide, with core US composition-of-matter patents expected to run through approximately 2036; (2) clinical data superiority — tirzepatide has demonstrated superior weight loss outcomes versus semaglutide in the SURMOUNT-5 head-to-head trial; (3) manufacturing scale — producing biologics-grade injectables at the volumes required for tens of millions of patients is a substantial operational barrier; and (4) physician relationships and brand recognition in diabetes and endocrinology, built over 50+ years with Humalog and Trulicity. These factors create significant time and capital barriers for any competitor attempting to displace tirzepatide as the market-leading incretin.

Subsidies and regulatory credits. Eli Lilly does not rely on direct government subsidies in the traditional sense. However, the company benefits significantly from the US patent system and data exclusivity provisions under the Biologics Price Competition and Innovation Act (BPCIA), which prevent biosimilar competition for 12 years post-approval. Conversely, the Inflation Reduction Act (IRA) is a material risk: under IRA provisions, the US government can negotiate prices for Medicare Part D drugs, and tirzepatide is a candidate. The IRA-negotiated price takes effect in 2027 for Medicare patients, which could reduce net revenue per unit for the portion of demand covered by Medicare Part D.

R&D investment. Lilly invested approximately $10bn+ in research and development in FY2025, sustaining a pipeline of 50+ clinical-stage molecules. This represents approximately 15% of revenue. Unlike many large pharma companies, Lilly has chosen to concentrate its pipeline in incretin biology, oncology, immunology, and neuroscience rather than pursue broad diversification. This focused approach has produced the tirzepatide franchise but creates concentration risk if the incretin category faces clinical or commercial headwinds.

5. Financial Health

All figures sourced from Eli Lilly's FY2025 earnings press release and EDGAR XBRL data (CIK 0000059478). FCF = operating cash flow minus capital expenditures, per the FY2025 cash flow statement.

Fiscal year	Revenue	YoY %	GAAP EPS (diluted)	Adjusted EPS	Dividend/share	Long-term debt (YE)
FY2021	$28.32bn	+15.4%	$6.92	$8.15	$3.74	$15.35bn
FY2022	$28.54bn	+0.8%	$6.40	$7.53	$3.92	$14.74bn
FY2023	$34.12bn	+19.6%	$6.32	$8.65	$4.52	$18.32bn
FY2024	$45.04bn	+32.0%	$10.59	$13.37	$5.20	$28.53bn
FY2025	$65.2bn	+44.8%	$22.95	$24.21	$5.72	$40.87bn

Note: FY2021–FY2024 GAAP EPS and Adjusted EPS are sourced from Lilly's annual results press releases and EDGAR filings. LT debt figures are noncurrent long-term debt from the balance sheet per SEC EDGAR XBRL (LongTermDebtNoncurrent concept). FY2025 LT debt $40.87bn confirmed via EDGAR XBRL. FY2025 GAAP EPS $22.95 confirmed from quarterly sum (Q1 $3.06 + Q2 $6.29 + Q3 $6.21 + Q4 $7.39). FY2025 Adjusted EPS $24.21 per company press release. Dividend figures are approximate annual totals from quarterly payments.

Quarterly revenue (FY2025–Q1 2026, most recent first):

Quarter	Revenue	Operating EPS	GAAP EPS
Q1 2026	$19.8bn	$8.55	$8.26
Q4 2025	$19.3bn	$7.54	$7.39
Q3 2025	$17.6bn	$7.02	$6.21
Q2 2025	$15.56bn	$6.31	$6.29
Q1 2025	$12.73bn	$3.34	$3.06
FY2025 total	$65.2bn	$24.21	$22.95

Free cash flow and capital allocation. FCF was $8.97bn in FY2025 (operating cash flow $16.81bn minus capital expenditures $7.84bn, per EDGAR XBRL). This represents a significant improvement from FY2024 FCF of $3.76bn (OCF $8.82bn minus capex $5.06bn) and FY2023 FCF of $0.79bn (OCF $4.24bn minus capex $3.45bn), which reflected the peak capex build-out phase. Capex is expected to remain elevated ($7–9bn annually) through the manufacturing expansion programme. Cash and equivalents stood at approximately $7.3bn at FY2025 year-end, against $40.87bn in noncurrent long-term debt — a net debt position reflecting the bond-funded manufacturing programme. LLY has maintained its dividend, paying $1.43 per quarter ($5.72/year) in FY2025, representing a modest yield of ~0.5% at current valuations.

Share count. Diluted weighted average shares were approximately 897–900 million for FY2025. Lilly has not pursued aggressive buybacks; capital is being directed to manufacturing expansion and R&D rather than capital returns. The diluted share count has been broadly flat over the five-year period.

6. Valuation & Market Data

Raw metrics, May 2026. Not opinions on whether the stock is cheap or expensive.

Metric	Value
Market cap	~$951bn (May 2026, per web search)
Enterprise value	~$987bn (market cap + $40.87bn LT debt − ~$7.3bn cash)
Trailing P/E (GAAP)	~46.0x (price ~$1,058 / FY2025 GAAP EPS $22.95)
P/E (forward)	~26.7x (per web search, May 2026, based on consensus non-GAAP estimates)
P/S (TTM)	~14.6x ($951bn / $65.2bn FY2025 revenue, per web search May 2026)
EV/EBITDA (TTM)	~35x (EV ~$987bn / estimated EBITDA ~$28bn)
P/FCF	~106x ($951bn / $8.97bn FY2025 FCF)
52-week high	$1,133.95
52-week low	$623.78
Dividend yield	~0.54% ($5.72 annual dividend at ~$1,058/share)
Short interest (% of float)	~0.87% (per web search, May 2026)
Days to cover	~1–2 days (low short interest, high liquidity)

Note: EBITDA estimated as GAAP net income ~$20.6bn + D&A ~$2.0bn (per EDGAR XBRL) + estimated interest expense ~$1.6bn + estimated income tax ~$4bn. EV/EBITDA is an approximation; use company-reported EBITDA when available. Forward P/E is based on consensus non-GAAP estimates per web search and will move with revisions to FY2026 guidance. Short interest sourced from web search May 2026.

7. What Are They Building / What's Coming?

Oral GLP-1 — Foundayo (orforglipron) launched April 2026. Lilly became one of the first companies to bring an oral small-molecule GLP-1 receptor agonist to market, with Foundayo approved by the FDA for type 2 diabetes in April 2026. Unlike injectable GLP-1s, orforglipron is a once-daily oral tablet, removing the injection barrier for many patients. Clinical trial data showed HbA1c reductions comparable to injectable GLP-1 analogues, though with lower absolute weight-loss efficacy than injectable tirzepatide. Oral tirzepatide (OFORLA programme) is also in development and, if approved, would offer the GIP/GLP-1 dual mechanism in pill form.

Retatrutide — triple agonist in Phase 3. Retatrutide (GIP/GLP-1/glucagon triple receptor agonist) has demonstrated weight-loss outcomes of up to 24% body weight reduction in Phase 2 trials — potentially exceeding tirzepatide in efficacy. Phase 3 trials (TRIUMPH programme) are underway in obesity and type 2 diabetes. If approved, retatrutide would represent the next generation of Lilly's incretin franchise and extend patent-protected revenue beyond the tirzepatide cycle.

Kisunla (donanemab) — Alzheimer's disease. Donanemab received FDA approval in July 2024 as Kisunla for the treatment of early symptomatic Alzheimer's disease in adults with amyloid pathology. Kisunla targets amyloid plaques and demonstrated a 35% slowing of cognitive decline in the TRAILBLAZER-ALZ 2 Phase 3 trial. Commercial uptake has been gradual given diagnostic complexity and infusion requirements, but management has guided that Kisunla represents a significant long-term revenue opportunity as the Alzheimer's market develops.

Manufacturing expansion. Lilly has committed over $23bn in US manufacturing investment since 2023, spanning new facilities in Indiana (Lebanon), North Carolina (Concord), and international sites in Germany and Ireland. On 6 May 2026, the company announced a further $4.5bn expansion of its Indiana manufacturing campus — the third major investment announcement for that site. These investments are aimed at scaling injectable and oral GLP-1 manufacturing to meet projected demand for Mounjaro, Zepbound, Foundayo, and future pipeline products.

Pipeline breadth. Beyond incretin biology, Lilly has 50+ molecules in clinical development including: lepodisiran (small interfering RNA targeting Lp(a) for cardiovascular disease, Phase 3), lebrikizumab/Ebglyss (atopic dermatitis, expanding internationally after EU and UK approvals), pirtobrutinib/Jaypirca (B-cell malignancies, growing oncology franchise), and multiple early-stage programmes in immunology and neurodegeneration. Management has guided that new pipeline molecules are expected to contribute materially to revenue in the 2027–2032 window.

FY2026 guidance. At the Q1 2026 earnings call (April 2026), management raised FY2026 revenue guidance to $82–85bn, implying growth of approximately 26–30% YoY. Non-GAAP EPS guidance was revised upward, reflecting manufacturing capacity increasing ahead of schedule at several new Indiana sites.

8. Competitive Landscape

The incretin (GLP-1/GIP) market is the most consequential growth market in global pharmaceuticals. Lilly competes primarily against Novo Nordisk in the diabetes and obesity segments, and against a broader set of large-cap pharmaceutical companies in oncology, immunology, and neuroscience.

GLP-1/incretin competition. Novo Nordisk's semaglutide (Ozempic for diabetes, Wegovy for obesity) is the primary competitor to tirzepatide. While tirzepatide has demonstrated superior weight-loss outcomes in head-to-head trials, semaglutide has strong physician familiarity, a first-mover advantage in obesity, and a maturing oral form (Rybelsus). Long-term, the competition will be defined by outcomes data in cardiovascular risk reduction (Mounjaro's SURPASS-CVOT), kidney disease, and non-alcoholic steatohepatitis (NASH). Other emerging GLP-1 challengers include Viking Therapeutics (VK2735, Phase 3), Roche (CT-388 and CT-996), Amgen (MariTide), and Structure Therapeutics — all at earlier stages but potentially entering market 2027–2029.

Oncology competition. Verzenio (abemaciclib) competes with Pfizer's Ibrance (palbociclib) and Novartis's Kisqali (ribociclib) in CDK4/6 inhibitors for breast cancer. Verzenio has differentiated itself via adjuvant data in early-stage high-risk breast cancer, making it the preferred agent in that sub-setting.

Policy impact. The Inflation Reduction Act's Medicare drug price negotiation provisions are a direct competitive factor. Both Lilly and Novo Nordisk face potential government-negotiated price reductions on their GLP-1 drugs for Medicare Part D patients. Novo Nordisk faces the same risk with semaglutide. Companies with lower US revenue concentration in Medicare populations face less acute exposure. Government subsidies are not a material factor in this sector beyond the Medicare/Medicaid reimbursement system and the patent protection framework.

Peer	Market Cap (May 2026)	FY2025 Revenue	P/E (TTM, May 2026)	Key differentiator
Novo Nordisk (NVO)	~$340bn (per web search May 2026)	DKK 232.3bn / ~$34bn (per FY2024 annual report; FY2025 est. ~$40bn)	~25x	Ozempic/Wegovy (semaglutide, GLP-1 pioneer); first-mover in obesity; oral semaglutide (Rybelsus). Primary GLP-1 rival; tirzepatide head-to-head shows Lilly's weight-loss superiority but Novo has deeper market penetration in obesity.
Pfizer (PFE)	~$135bn (per web search May 2026)	~$63bn (per FY2025 press release)	~12x	Broad diversified pharma including oncology (Ibrance), vaccines, and generics; no major GLP-1 presence. Significantly lower valuation reflects post-COVID portfolio normalisation and patent cliff concerns.
AstraZeneca (AZN)	~$275bn (per web search May 2026)	~$54bn (per FY2025 results)	~25x	Oncology-led (Tagrisso, Lynparza, Enhertu collaboration) and cardiovascular/metabolic (Farxiga). No GLP-1 franchise; differentiated by oncology breadth.
Merck (MRK)	~$260bn (per web search May 2026)	~$64bn (per FY2025 annual report)	~14x	Keytruda (pembrolizumab) is the world's best-selling drug by revenue; Gardasil HPV vaccine. Keytruda's patent cliff ~2028–2029 is a key risk; no GLP-1 exposure.
Johnson & Johnson (JNJ)	~$400bn (per web search May 2026)	~$90bn (per FY2025 annual report; pharma + MedTech)	~15x	Diversified pharmaceutical and MedTech; oncology (Darzalex, Erleada), immunology (Stelara, Tremfya). No GLP-1 programme; lower growth multiple reflects portfolio maturity.

9. Leadership and Ownership

David A. Ricks — Chairman and CEO. Ricks joined Lilly in 1996 and became President and CEO in January 2017, adding the Chairman role in 2018. Prior to becoming CEO, he led Lilly's international operations and its biomedicines division. Under his leadership, Lilly has transformed from a mid-sized diabetes company into the world's most valuable pharmaceutical company, principally driven by the strategic bet on tirzepatide and GLP-1 biology. He has presided over the largest manufacturing investment in Lilly's history.

Board and governance. Lilly's board includes directors with backgrounds in healthcare, technology, and finance. The company has a classified board structure; director backgrounds and committee assignments are listed in the most recent proxy statement at investor.lilly.com. Institutional Shareholder Services (ISS) and Glass Lewis governance ratings should be consulted by investors concerned with governance quality.

Insider ownership. Executive insider ownership is relatively modest as a percentage of total market cap given Lilly's ~$951bn size. David Ricks's beneficial ownership is below 1% of total shares. Management compensation is primarily performance-based (RSUs and PSUs tied to revenue and EPS milestones), aligning incentives with shareholders.

Institutional holders. Major institutional shareholders include Vanguard Group (~8%), BlackRock (~6%), State Street Corporation (~4%), and Capital Research and Management (~3%), per web search May 2026. These are approximate figures and change quarterly with 13F filings.

Insider transactions.

No material discretionary open-market purchases found in SEC Form 4 filings for the past 12 months. Most insider transactions during this period were pre-planned 10b5-1 programme disposals by executives exercising vested options and RSUs. Check SEC EDGAR Form 4 filings at sec.gov/cgi-bin/browse-edgar for LLY for current data.

Name	Date	Type	Shares	Price	Value	Plan type
No material discretionary insider transactions identified in SEC Form 4 search for LLY (past 12 months). Routine 10b5-1 plan disposals by executives occurred during the period; see sec.gov EDGAR for complete filings.

10. Risks and Challenges

• IRA Medicare price negotiation (Regulatory): Under the Inflation Reduction Act, the US Department of Health and Human Services can negotiate prices for high-spend Medicare Part D drugs. Tirzepatide (Mounjaro/Zepbound) is a candidate for future negotiation cycles, which could reduce US net realised prices for Medicare patients — a significant revenue risk given the US-heavy tirzepatide revenue base.
• GLP-1 competitive intensification (Competitive): Novo Nordisk's semaglutide franchise, plus advancing oral GLP-1 candidates from Roche (CT-388), Viking Therapeutics (VK2735), Amgen (MariTide), and others, threaten tirzepatide's long-term pricing power and market share. If a competitor achieves superior efficacy or a more convenient dosing form, uptake could slow materially from current growth trajectories.
• Manufacturing execution risk (Operational): The $23bn+ US manufacturing expansion is the largest capital programme in Lilly's history. Construction delays, FDA inspection findings at new sites, or quality control failures could constrain supply and defer revenue recognition, particularly for new oral and injectable GLP-1 products.
• High valuation concentration risk (Financial): At P/FCF ~106x and EV/EBITDA ~35x, the valuation embeds substantial execution assumptions. A clinical failure in retatrutide or Kisunla, slower tirzepatide adoption, or a pricing event could lead to significant multiple compression even if the underlying business continues growing.
• Patent cliff (Financial): Tirzepatide's core US composition-of-matter patents expire approximately 2036. Beyond that date, biosimilar or generic competition would compress pricing materially. Lilly must sustain pipeline productivity to replace tirzepatide revenue. Verzenio faces CDK4/6 biosimilar competition from approximately 2027–2030 depending on jurisdiction.
• Clinical trial failure risk (Operational): Pharmaceutical R&D carries inherent failure risk at all stages. Retatrutide Phase 3 results, Kisunla real-world safety data, and oral tirzepatide bioavailability data are all material binary events. A Phase 3 failure in retatrutide, in particular, would remove a key long-term growth pillar.
• Geopolitical and tariff exposure (Macro): Proposed US tariffs on pharmaceutical imports could affect Lilly's manufacturing costs at its international sites (Germany, Ireland). Conversely, Lilly's US domestic manufacturing expansion positions it relatively well in a tariff environment versus peers with higher offshore manufacturing ratios.
• GAAP earnings quality (Financial): Acquired in-process R&D charges, amortisation of intangibles from acquisitions, and other non-recurring items create a persistent gap between GAAP and non-GAAP earnings. Investors should track both metrics; periods of heavy acquisition activity can significantly suppress GAAP results.
• Key person risk (Operational): David Ricks has led Lilly's strategic transformation since 2017. Succession planning, while standard in large-cap companies, is a factor given the importance of long-term capital allocation decisions in pharmaceutical R&D.

11. Recent Developments

• 06 May 2026 — $4.5bn additional Indiana manufacturing investment announced. Eli Lilly announced a further $4.5bn expansion of its Lebanon, Indiana manufacturing campus, building on prior announcements of $9bn+ for that site. The investment targets additional capacity for injectable and oral GLP-1 medicines, with construction expected to create thousands of construction-phase jobs. This brings Lilly's total US manufacturing commitment since 2020 to over $23bn.
• 30 Apr 2026 — Q1 2026 earnings: revenue $19.8bn, GAAP EPS $8.26. Lilly reported Q1 2026 revenue of $19.8bn (per company earnings release), exceeding prior guidance. Non-GAAP EPS was $8.55. Management raised FY2026 revenue guidance to $82–85bn and non-GAAP EPS guidance upward, citing stronger-than-expected demand for Mounjaro and Zepbound as supply constraints ease at new manufacturing sites.
• Apr 2026 — Foundayo (orforglipron) FDA approval and US launch. The FDA approved orforglipron (Foundayo) for the treatment of type 2 diabetes in adults, making it one of the first oral non-peptide GLP-1 receptor agonists to reach market. Lilly commenced the US commercial launch of Foundayo in April 2026, positioning it as a complement to the injectable tirzepatide franchise for patients preferring oral therapy.
• 11 Feb 2026 — FY2025 full-year results. Lilly reported FY2025 revenue of $65.2bn (up 44.8% YoY), GAAP net income ~$20.6bn, and diluted GAAP EPS of $22.95. Mounjaro and Zepbound were the primary growth drivers. The company announced an increase in the quarterly dividend to $1.50 per share (FY2026 rate), an increase from $1.43 in FY2025.
• Jul 2025 — Kisunla commercial rollout progressing. Following FDA approval in July 2024, Lilly's donanemab (Kisunla) continued its commercial rollout for early symptomatic Alzheimer's disease during 2025. Uptake has been gradual given requirements for amyloid PET or CSF testing to confirm eligibility; management acknowledged the diagnostic bottleneck but expressed confidence in long-term market development. Kisunla's TRAILBLAZER-ALZ 3 prevention trial continues.
• 2026 — 150th anniversary year. Eli Lilly marks its 150th year in operation in 2026, having been founded by Colonel Eli Lilly in Indianapolis on 10 May 1876. The company has commissioned commemorative activities and used the milestone in investor communications to highlight its long-term scientific heritage. For investor relations and regulatory filings, visit the ChartsView Forum or Economic Calendar.

12. Key Dates Coming Up

• Expected late July / early August 2026 — Q2 2026 earnings release and conference call (exact date to be confirmed at investor.lilly.com; typically 4–6 weeks after quarter end).
• Expected Aug 2026 — Ex-dividend date for Q3 2026 quarterly dividend (confirm exact date at investor.lilly.com/dividends).
• 2026 (ongoing) — Retatrutide Phase 3 TRIUMPH trial interim data readouts expected; management has guided on mid-to-late 2026 data milestones.
• 2026 (ongoing) — Oral tirzepatide Phase 3 trial data expected; positive results would be a major catalyst for the next generation of the tirzepatide franchise.
• 2027 (expected) — IRA-negotiated Medicare price for tirzepatide takes effect; the impact on net US revenue per unit is a key monitoring item.

Disclaimer: This research is produced by ChartsView for educational and informational purposes only. It does not constitute financial advice or a recommendation to buy or sell any security. All information is sourced from publicly available company filings, press releases, and official data. ChartsView does not use analyst opinions or third-party ratings. Always conduct your own due diligence and consider your personal financial situation before making investment decisions. Past performance is not indicative of future results.

Explore related resources: Live Charts | Economic Calendar | Forum | Blog